MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Istradefylline

CAS No. : 155270-99-8

MCE 站：Istradefylline

产品活性：Istradefylline 是一种有效的，选择性的，可口服的 adenosine A2A receptor 拮抗剂，在帕金森疾病模型试验中，K_i 值为 2.2 nM。

研究领域：GPCR/G Protein

作用靶点：Adenosine Receptor

In Vitro: Istradefylline has 70-fold greater affinity for the A2AR than the A1 receptor with K_i of 2.2 nM versus 150 nM. Istradefylline causes concentration-dependent abolition of bFGF induction of astrogliosis in primary rat striatal astrocytes. Istradefylline binds to A1 receptor, A2A receptor, and A3 receptor in human with K_is of >287 nM, 9.12 nM, and >681 nM, respectively, 50.9 nM and 1.57 nM for A1 receptor and A2A receptor in rat, 105.02 nM and 1.87 nM for A1 receptor and A2A receptor in mouse, respectively.

In Vivo: Istradefylline (3.3 mg/kg, i.p.) treatment before a single dose of MPTP attenuates the partial dopamine and DOPAC depletions measured in striata 1 week later. Istradefylline reverses CGS21680-induced and reserpine-induced catalepsy with an ED₅₀ of 0.05 mg/kg and 0.26 mg/kg, respectively. Istradefylline is over 10 times as potent in these models compared to other adenosine antagonists and dopamine agonist drugs. Istradefylline combined with L-dopa cuases potent effects on haloperidol-induced and reserpine-induced catalepsy. Istradefylline (10 mg/kg, p.o.) results an increase in locomotor activity to approximately twice that of control and improves motor disability in MPTP-treated common marmosets. Istradefylline (10 mg/kg, p.o.) in combination with SKF80723, quinpirole, or L-DOPA produces a significant additive effect on locomotor activity and improvement of motor disability but not dysK_inesia.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  FDA-Approved Drug Library  |  Small Molecule Immuno-Oncology Compound Library  |  Drug Repurposing Compound Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  ZM241385  |  CGS 21680 Hydrochloride  |  5'-N-Ethylcarboxamidoadenosine  |  SCH 58261  |  Theophylline  |  Inosine  |  BAY 60-6583  |  MRS 1754  |  Piclidenoson  |  Namodenoson  |  MRS-1191  |  Regadenoson  |  Ticlopidine hydrochloride  |  Aminophylline  |  CGS 15943  |  Diphylline  |  MRS-1706  |  Adenosine 5'-monophosphate monohydrate  |  Capadenoson  |  GR79236  |  N6-(2-Phenylethyl)adenosine  |  Tecadenoson  |  Doxofylline  |  PD 117519  |  APNEA  |  Derenofylline  |  LAS101057  |  N6-Cyclohexyladenosine  |  N6-Cyclopentyladenosine  |  Theobromine

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。